The Global GERD Drug and devices market is anticipated to grow at a CAGR of 1.12% between 2019 and 2027. Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder. It is defined as the complications arising from the backflow of gastric contents into the esophagus due to weakened lower esophageal sphincter (LES). The following factors primarily drive the GERD Drug and devices market:

• Growing trend of self-medication
• Increasing awareness about GERD
• Increasing occurrence of GERD disorders
• Changes in lifestyle

The important drivers increasing growth in the global GERD Drug and devices Market are increasing awareness about GERD and Increasing occurrence of GERD disorders. Awareness among individuals about GERD and its complications is increasing nowadays. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade.

The Drugs and devices of GERD Drug and devices market are used extensively for various purposes. Antacids are preferred as first-line therapy for mild and infrequent symptoms as they immediately neutralize gastric acid secretions. The body well absorbs H2 receptor blockers and provide quick relief from the esophagus symptoms. Proton pump inhibitors inhibit gastric acid secretion by inhibition of the H+/K+ ATPase enzyme system in the gastric parietal cells. Pro-kinetic agents, also known as promobility agents, stimulate the muscles of the gastrointestinal tract and strengthen lower esophageal sphincter, thereby reducing acid reflux into the esophagus. Digitrapper reflux testing system observes & records the extra-esophageal symptoms of acid reflux. The Bravo System is a diagnostic system to determine the frequency & duration of acid reflux. MUSE is an endoscopic device used for transoral fundoplication. The Other devices are Endostim Neurostimulation System, EsophyX. Endostim Neurostimulation System is a system consists of Neurostimulator (IPG), implantable bipolar lead & wireless external programmer.

Patent Expiry and Adverse Effect of Proton Pump Inhibitors and Other Drugs are the major factors hindering the GERD Drug and devices market. In recent years, several drugs to treat GERD lost their patent protection in the U.S. and other countries worldwide. Every drug taken by patients for disease treatment has certain adverse effects.

The Global GERD Drug and devices market segments include Drugs and devices.

Drugs and devices are segmented into:

• Drug class
  • Antacids
  • H2 receptor blockers
    • Cimetidine
    • Famotidine
    • Nizatidine
    • Ranitidine HCL
  • Proton pump inhibitors (PPI)
    • Nexium
    • Prilosec/ Losec
    • Aciphex/ Pariet
    • Dexilant
    • Protonix
    • Prevacid
    • Zegerid
    • Other generic PPI
  • Pro-kinetic agents
• Devices
  • Digitrapper
  • Bravo system
  • Stretta
  • Linx reflux management system
  • Muse (medigus ultrasonic surgical endostapler) system
  • Other devices

This report covered the present market conditions and the growth prospects of the global GERD Drug and devices market for 2019-2027 and considered the revenue generated through the sales of GERD Drug and devices for Drugs and devices to calculate the market size by considering 2018 as the base year.

Geographically, the global GERD Drug and devices market has been segmented on the basis of four major regions, which include:

• North America: The United States & Canada
• Asia-Pacific: China, India, Japan, Australia, South Korea & Rest of APAC
• Europe: The United Kingdom, France, Germany, Italy, Spain & Rest of Europe
• Rest of World: Latin America & the Middle East and Africa

The GERD Drug and devices market in North America is expected to hold the largest share by 2027 possibilities of the presence of a large patient population suffering from heartburn and the availability of OTC generics. The rise in the incidence of GERD in North America is responsible for the increase in demand for acid reducing and neutralizing drugs. Also, the self-medication trend for management of digestive and gastrointestinal disorders has become popular, owing to convenience, time saved and cost-effectiveness. On the other hand, the Asia-Pacific market is anticipated to the fastest-growing region for the GERD Drug and devices market. The GERD market in Asia-Pacific is expected to grow at a justly high growth ratio as compared to other local markets due to the augmented acceptance of generic antacids and OTC along with the growing occurrence of heartburn.

The major market players of the global GERD Drug and devices market are:

• ASTRAZENECA
• EISAI INC
• NOVARTIS
• PFIZER, INC.
• TAKEDA PHARMACEUTICALS COMPANY LIMITED

Company Profiles covers analysis of important players.

AstraZeneca PLC (AstraZeneca or ‘the company’) is involved in discovery, development, manufacturing, and marketing of prescription pharmaceuticals and biological products in the therapeutic areas of cardiovascular, gastrointestinal, infection, neuroscience, oncology and respiratory. Takeda Pharmaceutical Company Limited (Takeda or ‘the company’), a leading pharmaceutical company in Japan, is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company develops new drug products in its 19 research and development sites and 19 production sites in 18 countries and regions worldwide.

Key Findings of the Global GERD Drug and devices market:

• Antacids drug class holds the largest market share
• Bravo system devices are widely used